Table 2.
Variable | Univariable Model | Multivariable Model (Base Model)a | ||||||
---|---|---|---|---|---|---|---|---|
Risk Ratio | (95% CI) | P Value | Global P Valueb | Adjusted Risk Ratio | (95% CI) | P Value | Global P Valueb | |
Age (per 10 y) at day 0 | 1.00 | (.89–1.12) | .96 | 0.99 | (.87–1.14) | .93 | ||
BMI (kg/m2) at day 0 | ||||||||
25–29.9 vs <25 [ref] | 0.76 | (.43–1.36) | .36 | .04 | 0.90 | (.49–1.63) | .72 | .11 |
30–34.9 vs <25 [ref] | 1.42 | (.81–2.47) | .22 | 1.65 | (.93–2.93) | .09 | ||
≥35 vs < 25 [ref] | 1.51 | (.85–2.67) | .16 | 1.40 | (.75–2.64) | .29 | ||
Cigarette smoking status at day 0 | ||||||||
Current vs never [ref] | 2.39 | (1.41–4.06) | .001 | .10 | 2.41 | (1.34–4.32) | .003 | .07 |
Former vs never [ref] | 1.04 | (.63–1.74) | .87 | 0.85 | (.49–1.47) | .56 | ||
Ethnicity | ||||||||
Hispanic or Latino vs not [ref] | 0.49 | (.31–.78) | .003 | 0.52 | (.32–.84) | .007 | ||
High-risk comorbiditiesc | ||||||||
At least 1 vs non/not reported [ref] | 1.31 | (.90–1.93) | .16 | 1.15 | (.72–1.84) | .56 | ||
Race | ||||||||
Black or African American vs White [ref] | 1.15 | (.51–2.57) | .74 | .71 | 1.14 | (.52–2.50) | .75 | .85 |
Other vs White [ref] | 0.73 | (.29–1.87) | .52 | 0.81 | (.31–2.12) | .67 | ||
Sex | ||||||||
Female vs male [ref] | 1.81 | (1.22–2.69) | .003 | 1.91 | (1.28–2.85) | .001 | ||
Total symptom score at day 0 (per unit higher) | 1.03 | (1.00–1.06) | .09 | 1.01 | (.98–1.05) | .41 |
Abbreviations: BMI, body mass index; CI, confidence interval; Non, none; ref=reference.
Multivariable model includes all variables together in 1 model.
Global P values provided for categorical variables with >2 categories.
High-risk comorbidities include active cancer, moderate to severe asthma, chronic kidney disease, chronic liver disease, history of cirrhosis, chronic lung disease, current smoker, cardiovascular disease, diabetes, hypertension, treatment with biologics/immunomodulators/cancer chemotherapy within 90 days of entry, human immunodeficiency virus with CD4 count <200 cells/μL, receiving corticosteroids within 30 days of entry, and obesity.